Novo Nordisk A S annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Capital Expenditures (CapEx) Growth & History (NVO)
Novo Nordisk A S's capital expenditures (capex) was kr60.14B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr60.14B | kr12.98B | +27.51% |
| 2024 | 2024-12-31 | kr47.16B | kr21.36B | +82.76% |
| 2023 | 2023-12-31 | kr25.81B | kr13.66B | +112.47% |
| 2022 | 2022-12-31 | kr12.15B | kr5.81B | +91.73% |
| 2021 | 2021-12-31 | kr6.33B | kr510.0M | +8.76% |
| 2020 | 2020-12-31 | kr5.83B | −kr3.11B | −34.79% |
| 2019 | 2019-12-31 | kr8.93B | — | — |
Novo Nordisk A S quarterly capital expenditures (capex)
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr12.68B | −kr1.99B | −13.55% |
| Q1 2026 | 2026-03-31 | kr12.04B | −kr1.38B | −10.30% |
| Q4 2025 | 2025-12-31 | kr18.43B | kr2.33B | +14.46% |
| Q3 2025 | 2025-09-30 | kr13.63B | kr1.51B | +12.45% |
| Q2 2025 | 2025-06-30 | kr14.66B | kr4.19B | +40.03% |
| Q1 2025 | 2025-03-31 | kr13.42B | kr4.95B | +58.39% |
| Q4 2024 | 2024-12-31 | kr16.10B | — | — |
| Q3 2024 | 2024-09-30 | kr12.12B | — | — |
| Q2 2024 | 2024-06-30 | kr10.47B | — | — |
| Q1 2024 | 2024-03-31 | kr8.47B | — | — |
Novo Nordisk A S capital expenditures (capex) trends
Over the last five fiscal years, Novo Nordisk A S's capital expenditures (capex) increased from kr5.83B to kr60.14B, a change of kr54.31B. The latest reported quarter, Q2 2026, shows kr12.68B.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...